Effects of nimodipine administration during cardiopulmonary resuscitation in pigs.
The haemodynamic effects of nimodipine during cardiopulmonary resuscitation (CPR) were investigated in 25 anaesthetized pigs. After 5 min of ventricular fibrillation (VF) and 5 min of closed-chest CPR, adrenaline (50 micrograms kg-1), either nimodipine (10 micrograms kg-1 as a bolus followed by 1 microgram kg-1 min-1 continuously) or the equivalent volume of placebo (solvent for nimodipine) were administered followed by the first countershock. If this failed to restore spontaneous circulation, adrenaline and countershocks were repeated for a maximum of 30 min. CPR was successful in nine out of 10 nimodipine-treated animals, but only in six out of 15 placebo-treated animals (P less than 0.02). In resuscitated pigs there were no significant differences in the number of countershocks, the number of seconds required for restoration of spontaneous circulation and the total doses of adrenaline required for both nimodipine and placebo pigs. After restoration of spontaneous circulation haemodynamic responses to nimodipine were characterized by decreases in systemic vascular resistance and mean arterial pressure with consequent increases in heart rate and cardiac output, but they were not significantly different from those of the placebo-treated animals. We therefore conclude that high doses of nimodipine are well tolerated during and after CPR; nimodipine administration may even result in higher initial CPR success rates. The underlying mechanisms need further investigation.
Schindler
I
I
Ludwig Boltzmann Institute of Experimental Anaesthesia, Vienna, Austria.
Mauritz
W
W
Weindlmayr-Goettel
M
M
Steinbereithner
K
K
D000818:Animals; D016280:Atrial Function, Right / Q000187:drug effects / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002245:Carbon Dioxide / Q000097:blood; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D002560:Cerebrovascular Circulation / Q000187:drug effects / Q000502:physiology; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology; D004554:Electric Countershock; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects; D007427:Intracranial Pressure / Q000187:drug effects / Q000502:physiology; D007773:Lactates / Q000097:blood; D009553:Nimodipine / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011651:Pulmonary Artery / Q000502:physiology; D011669:Pulmonary Wedge Pressure / Q000187:drug effects / Q000502:physiology; D012151:Resuscitation; D013552:Swine; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology; D014693:Ventricular Fibrillation / Q000503:physiopathology / Q000628:therapy
D007773:Lactates; D010919:Placebos; D002245:Carbon Dioxide; D009553:Nimodipine